PDK Labs, Inc. v. Proactive Labs, Inc.

325 F. Supp. 2d 176, 2004 U.S. Dist. LEXIS 17741, 2004 WL 1607703
CourtDistrict Court, E.D. New York
DecidedJuly 15, 2004
Docket1:03-cv-00772
StatusPublished
Cited by9 cases

This text of 325 F. Supp. 2d 176 (PDK Labs, Inc. v. Proactive Labs, Inc.) is published on Counsel Stack Legal Research, covering District Court, E.D. New York primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
PDK Labs, Inc. v. Proactive Labs, Inc., 325 F. Supp. 2d 176, 2004 U.S. Dist. LEXIS 17741, 2004 WL 1607703 (E.D.N.Y. 2004).

Opinion

MEMORANDUM AND ORDER

BLOCK, District Judge.

Plaintiff PDK Labs, Inc. (“PDK”) brought this action alleging trademark and trade dress infringement of its registered trademarks for “Two-Way” and “Max-brand” in the marketing of its over-the-counter bronchodilator medicine, along with related claims of unfair competition. Defendant Proactive Labs, Inc. (“Proactive”) has moved to dismiss pursuant to Fed.R.Civ.P. 12(b)(2) for lack of personal jurisdiction. Alternatively, Proactive moves for a change of venue to the Northern District of Georgia pursuant to 28 U.S.C. § 1391(b) and § 1404(a). For the reasons that follow, Proactive’s motions are denied.

I.

PDK brought this suit on February 18, 2003, seeking to prevent Proactive from launching an ephedrine bronchodilator medicine utilizing a “2-Way Ephedrine Max” trademark and trade dress. Proactive has not released this product, although it concedes that it hopes to launch the product in the future. See Oral Argument Transcript, June 8, 2004, at 13. Pursuant to a hearing held before the Court on March 11, 2003, PDK was granted the right to conduct discovery relating to the issue of whether Proactive’s contacts with New York State were sufficient to establish personal jurisdiction.

Because the parties have conducted jurisdictional discovery, PDK must aver facts that, if credited, would suffice to establish jurisdiction over Proactive, rath *179 er than merely pleading in good faith legally sufficient allegations of jurisdiction. See Ball v. Metallurgie Hoboken-Overpelt, S.A., 902 F.2d 194, 197 (2d Cir.1990). A plaintiffs averment of jurisdictional facts after discovery may be contested either by 1) a Rule 12(b)(2) motion challenging the sufficiency of the alleged facts, 2) a Rule 56 motion asserting that undisputed facts demonstrate the absence of jurisdiction, or 3) a request for an adjudication of disputed jurisdictional facts through a hearing or during the course of trial. See id. By filing a Rule 12(b)(2) motion, the defendant assumes the truth of plaintiffs factual allegations for purposes of the motion; therefore, “plaintiff need persuade the court only that its factual allegations constitute a prima facie showing of jurisdiction.” Id.

II.

A. Jurisdiction

“In a federal question case where a defendant resides outside the forum state, a federal court applies the forum state’s personal jurisdiction rules if the federal statute does not specifically provide for national service of process.” PDK Labs Inc. v. Friedlander 103 F.3d 1105, 1108 (2d Cir.1997) (quotation omitted). Therefore, “the court must first look to the long-arm statute of the forum state.” Bensusan Restaurant Corp. v. King, 126 F.3d 25, 27 (2d Cir.1997). “If the exercise of jurisdiction is appropriate under that statute, the court then must decide whether such exercise comports with the requisites of due process.” Id.

PDK argues that the Court has jurisdiction over Proactive under two subsections of New York’s long arm statute, N.Y. CPLR §§ 302(a)(1) and 302(a)(3). For the Court to have personal jurisdiction over a defendant under § 302(a)(1), the defendant must have transacted business in New York and the cause of action must arise out of those transactions. PDK Labs, 103 F.3d at 1109. See also Agency Rent A Car Sys. v. Grand Rent A Car Corp., 98 F.3d 25, 31 (2d Cir.1996) (requiring a “substantial nexus” between the business transacted and plaintiffs cause of action). Under § 302(a)(3), the Court can exercise jurisdiction over a non-domiciliary who “commits a tortious act without the state causing injury to person or property within the state ... if he (i) regularly does or solicits business, or engages in any other persistent course of conduct, or derives substantial revenue from goods used or consumed ... in the state, or (ii) expects or should reasonably expect the act to have consequences in the state and derives substantial revenue from interstate ... commerce.”

Because the Court determines that it has jurisdiction over Proactive under § 302(a)(3), it need not consider whether it would also have jurisdiction under § 302(a)(1).

1. Jurisdiction Under N.Y. CPLR § 302(a)(3)

PDK alleges that Proactive’s decision to package its ephedrine product in the “2-Way Ephedrine Max” packaging and its advertising and offering to sell the product in that allegedly infringing packaging constitute the requisite tortious act. In addition to having displayed the allegedly infringing trademark and trade dress on its website, which is maintained outside of New York but is, obviously, accessible within the state, Proactive concedes that it has also displayed the packaging at national trade shows outside of New York, and that it is likely that New York customers were in attendance at those shows. See Deposition of Kimberly Stratford, at 92. PDK alleges that this packaging caused injury in New York by confusing PDK’s New York customers and potential customers. Turning to § 302(a)(3)(ii), PDK *180 avers that Proactive’s awareness of PDK’s marks and that PDK has its principal place of business in New York are sufficient for Proactive to have reasonably expected its actions would have consequences in New York, and that Proactive derives substantial revenue from interstate commerce.

It is undisputed that PDK filed its lawsuit at a time when Proactive had started to market — but had not actually launched — its product, and that Proactive has never sold the product. Under § 302(a)(3), the threshold questions, therefore, are 1) whether a tortious act has been committed outside of New York State, and, if so, 2) whether it caused injury to person or property within New York State.

a. The Commission of a Tortious Act Outside of New York

At oral argument, counsel for Proactive argued that no tort had been committed because there had been no sales; therefore, jurisdiction under § 302(a)(3) must fail. See Oral Argument Transcript, June 8, 2004, at 3. Counsel for PDK argued that, because trademark law protects against the potential for consumer confusion, the threat of launching the product constituted a tort causing injury in New York. See id. at 6.

Trademark infringement, as codified in the Lanham Act, is not limited to situations where the infringing mark has been used in connection with the actual sale of a product. The Lanham Act imposes liability on any person who “use[s] in commerce any reproduction, counterfeit, copy, or col-orable imitation of a registered mark in connection with the sale, offering for sale, distribution, or

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Combe Inc. v. Dr. Aug. Wolff GmbH & Co. KG Arzneimittel
309 F. Supp. 3d 414 (E.D. Virginia, 2018)
Lebewohl v. Heart Attack Grill LLC
890 F. Supp. 2d 278 (S.D. New York, 2012)
Mangia Media Inc. v. University Pipeline, Inc.
846 F. Supp. 2d 319 (E.D. New York, 2012)
Energy Brands Inc. v. Spiritual Brands, Inc.
571 F. Supp. 2d 458 (S.D. New York, 2008)
Rockefeller University v. Ligand Pharmaceuticals Inc.
581 F. Supp. 2d 461 (S.D. New York, 2008)
NANOVIBRONIX, INC. v. Weiss
333 F. Supp. 2d 76 (E.D. New York, 2004)

Cite This Page — Counsel Stack

Bluebook (online)
325 F. Supp. 2d 176, 2004 U.S. Dist. LEXIS 17741, 2004 WL 1607703, Counsel Stack Legal Research, https://law.counselstack.com/opinion/pdk-labs-inc-v-proactive-labs-inc-nyed-2004.